AAV Production Process Intensification using Perfusion Bioreactor Technology

The therapeutic potential of gene therapy is transformative with the number of gene therapies rapidly increasing.

Pharmaron Biologics is a strategic partner for gene therapy developers and operates from state-of-the-art cGMP biomanufacturing facilities in Liverpool.

They apply pharma industry-leading expertise and cutting-edge technologies to support customers develop, test and commercialise their innovative medicines.

Pharmaron has entered a collaboration with Complement Therapeutics, an early-stage gene therapy company focusing on the development of novel therapeutics for complement-mediated diseases and Cell and Gene Therapy Catapult, an independent innovation and technology organisation supporting gene therapy developers advance faster to clinic to grow the UK economy.

The three organisations will combine efforts and expertise, to develop an intensified process for the production of gene therapies, with the aim to increase efficiency while improving the cost-effectiveness of manufacturing.

With the growing market demand for AAV products and shift from products targeting small population orphan and rare diseases, towards products targeting high-prevalence and systemic diseases, this collaboration will lay the foundation for the next generation of manufacturing platforms which will be needed to deliver the projected global gene therapy clinical needs, as well as improve patient access to these life-changing therapies.